Altered sarco(endo)plasmic reticulum calcium adenosine triphosphatase 2a content: Targets for heart failure therapy. (July 2018)

• Record Type: Journal Article
• Authors: Liu, Gang; Li, Si Qi; Hu, Ping Ping; Tong, Xiao Yong
• Is Part Of: Diabetes & vascular disease research. Volume 15:Number 4(2018:Jul.)
• Page Start: 322
• Page End: 335
• Publication Date: 2018-07
• Subjects: Sarco(endo)plasmic reticulum calcium adenosine triphosphatase -- calcium handling -- heart failure -- therapeutic target -- gene delivery; Diabetic angiopathies -- Periodicals; 616.462005
• DOI: 10.1177/1479164118774313
• Languages: English
• ISSNs: 1479-1641

Abstract

Sarco(endo)plasmic reticulum calcium adenosine triphosphatase is responsible for transporting cytosolic calcium into the sarcoplasmic reticulum and endoplasmic reticulum to maintain calcium homeostasis. Sarco(endo)plasmic reticulum calcium adenosine triphosphatase is the dominant isoform expressed in cardiac tissue, which is regulated by endogenous protein inhibitors, post-translational modifications, hormones as well as microRNAs. Dysfunction of sarco(endo)plasmic reticulum calcium adenosine triphosphatase is associated with heart failure, which makes sarco(endo)plasmic reticulum calcium adenosine triphosphatase a promising target for heart failure therapy. This review summarizes current approaches to ameliorate sarco(endo)plasmic reticulum calcium adenosine triphosphatase function and focuses on phospholamban, an endogenous inhibitor of sarco(endo)plasmic reticulum calcium adenosine triphosphatase, pharmacological tools and gene therapies.